FindTrial
Sign In

The association of 21-gene recurrence score assay and benifit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer across Guangxi

21-gene recurrence score assay and benifit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer across Guangxi

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-COC-17011125
Enrollment
Unknown
Registered
2017-04-12
Start date
2017-04-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Case series:None

Sponsors

The First Affiliated Hospital of Guangxi Medical Universtiy
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. patients with early-stage invasive breast cancer (I-IIIa stage); 2. Patient aged 18-75 years; 3. Patient's tumor must contain estrogen receptors (ER+/PR+); 4. Her2/Neu negative by IHC (0 or 1+) or FISH by current ASCO/CAP guidelines; 5. Patient has adequate performance status (PS ECOG 0,1 or Karnofsky =70); 6. Operable and plnning to undergo surgery; 7. Adequate material for the 21-gene recurrence score assay; 8. Patient must be able to give informed consent before any study assocaited treatments.

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating women; 2. Patients had other malignant tumor in 5 years; 3. Not able to complete study for mental disease or others; 4. Patients with other serious disease.

Design outcomes

Primary

MeasureTime frame
21-gene recurrence score assay;—

Countries

China

Contacts

Public ContactZeng Jian

The First Affiliated Hospital of Guangxi Medical Universtiy

zengjian125@hotmail.com+86 13978876125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026